

1 **Azithromycin Treatment Response as a Probe to Attribute Bacterial Aetiologies of**
2 **Diarrhoea using Molecular Diagnostics: A Reanalysis of the AntiBiotics for**
3 **Children with severe Diarrhoea (ABCD) Trial**

4
5 Jennifer Cornick¹, Sarah Elwood², James Platts-Mills², Patricia Pavlinac^{3,4}, Karim
6 Manji⁵, Chris Sudfeld⁶, Christopher P. Duggan^{6, 7}, Queen Dube¹, Naor Bar-Zeev⁸, Karen
7 Kotloff^{9,10}, Samba O Sow¹¹, Sunil Sazawal¹², Benson O Singa^{13,14}, Judd L Walson^{13,15},
8 Farah Qamar¹⁶, Tahmeed Ahmed¹⁷, Ayesha De Costa¹⁸, Elizabeth T Rogawski
9 McQuade¹⁹

10

11 Affiliations:

- 12 1. Department of Pediatrics, Queen Elizabeth Central Hospital, Blantyre, Malawi.
13 2. Division of Infectious Diseases and International Health, Department of Medicine,
14 University of Virginia, Charlottesville, VA, USA.
15 3. Department of Global Health, University of Washington, Seattle, WA, USA
16 4. Department of Epidemiology, University of Washington, Seattle, WA, USA.
17 5. Department of Pediatrics and Child Health, Muhimbili University of Health and Allied
18 Sciences, Dar es Salaam, Tanzania.
19 6. Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
20 Boston, MA, USA.
21 7. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital,
22 Boston, MA, USA
23 8. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health,
24 Baltimore, MD, USA.
25 9. Department of Pediatrics, Center for Vaccine Development and Global Health,
26 University of Maryland School of Medicine, Baltimore.
27 10. Department of Medicine, Center for Vaccine Development and Global Health, University
28 of Maryland School of Medicine, Baltimore, MD, USA.
29 11. Centre pour le Développement des Vaccins, Bamako, Mali.
30 12. Center for Public Health Kinetics, New Delhi, Delhi, India.

- 31 13. Childhood Acute Illness and Nutrition Network, Nairobi, Kenya.
- 32 14. Kenya Medical Research Institute, Nairobi, Kenya
- 33 15. Departments of International Health, Medicine and Pediatrics, Johns Hopkins University,
- 34 Baltimore, MD, USA
- 35 16. Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
- 36 17. Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease
- 37 Research, Dhaka, Bangladesh
- 38 18. Department of Maternal, Child, and Adolescent Health and Aging, World Health
- 39 Organization, Geneva, Switzerland
- 40 19. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta,
- 41 GA, USA
- 42

43 **Abstract**

44 **Background**

45 Multi-pathogen molecular diagnostics enable assignment of diarrhoea aetiology, but
46 defining thresholds of pathogen quantity to accurately attribute aetiology is challenging
47 in high-burden settings where coinfections are common. The Antibiotics for Children
48 with severe Diarrhoea (ABCD) trial provides an opportunity to leverage the azithromycin
49 treatment response to inform which diarrhoea episodes are bacterial.

50

51 **Methods**

52 We analysed data from ABCD, which randomized children with watery diarrhoea to
53 azithromycin or placebo. We quantified heterogeneity in the azithromycin treatment
54 response by the quantity of enteric pathogens detected by qPCR as a tool for
55 understanding aetiology.

56

57 **Results**

58 The heterogeneity in azithromycin treatment response was most prominent for *Shigella*.
59 The risk ratio for diarrhoea on day 3 post enrolment for azithromycin compared to
60 placebo was 13% (95% CI:3, 23) lower per log₁₀ increase in *Shigella* quantity. The
61 protective effect of azithromycin on diarrhoea at day 3 also became stronger as
62 pathogen quantities increased for *Vibrio cholerae*, ST-EPEC, and tEPEC. No
63 association between pathogen quantity and azithromycin response was observed for

64 *Campylobacter*, LT-ETEC or EAEC. The associations were consistent for the outcome
65 of 90-day hospitalisation or death.

66

67 **Conclusions**

68 The relationships between response to azithromycin treatment and bacterial pathogen
69 quantities observed for *Shigella*, *Vibrio cholerae*, ST-ETEC and tEPEC confirm prior
70 evidence that these pathogens are the likely cause of diarrhoea when detected at high
71 quantities. The lack of a similar response pattern for *Campylobacter*, LT-ETEC or EAEC
72 is consistent with the limited association between pathogen quantity and diarrhoea
73 symptoms previously observed in large studies of diarrhoea aetiology.

74

75 **Key message** (3 succinct bullet points, each a single sentence)

76 1. We investigated whether heterogeneity in treatment response observed in the
77 ABCD trial, where children with diarrhoea were randomised to receive
78 azithromycin or placebo, could be used to inform aetiological attribution of
79 diarrhoea to bacterial enteric pathogens.

80
81 2. The protective effect of azithromycin on diarrhoea at day 3 and hospitalisation or
82 death at day 90 became stronger as pathogen quantities increased for *Shigella*,
83 *Vibrio cholerae*, *ST-EPEC* and *tEPEC* but not for *Campylobacter*, LT-EPEC or
84 EAEC.

85
86 3. The relationships between *Shigella*, *Vibrio cholerae*, ST-EPEC and tEPEC
87 quantity and response to antibiotic treatment confirm prior evidence that these
88 pathogens are the likely cause of diarrhoea when detected at high quantities and
89 could be used to inform which diarrhoea cases should be treated with antibiotics.

90

91 Introduction

92 Diarrhoeal diseases are the second leading cause of death in children under five, with
93 the highest burden of disease experienced in low- and middle- income countries
94 (LMICs) (1). Accurate estimates of the burden of specific aetiologies of diarrhoea are
95 necessary for global resource allocation and policy making and may be useful to inform
96 appropriate treatment measures beyond the WHO IMCI recommended management
97 (2). Quantitative PCR (qPCR) diagnostics have been used to attribute likely diarrhoea
98 aetiologies in multiple large global studies, including the Global Enteric Multicentre
99 Study (GEMS) (3), the Malnutrition and the Consequences for Child Health and
100 Development (MAL-ED) study (4), and the Global Paediatric Diarrhoea Surveillance
101 network (5).

102

103 The Antibiotics for Children with severe Diarrhoea (ABCD) study, a 7-country,
104 randomized, double-blinded, placebo-controlled trial assessed if a 3-day course of
105 azithromycin reduced mortality or improved linear growth among children with acute
106 watery diarrhoea accompanied by dehydration or undernutrition (6). Rotavirus (21.1%)
107 was the leading cause of diarrhoea, while 28.3% of diarrhoeal cases had a likely
108 bacterial aetiology, most commonly *Shigella*, ST-EPEC, and typical EPEC (7). While the
109 impact of azithromycin among all enrolled children was minimal, molecular diagnostics
110 revealed that azithromycin was effective at reducing risk of day 3 diarrhoea and day 90
111 hospitalization or death among children with likely bacterial diarrhoea (7). Due to the
112 absence of diarrhoea-free controls in ABCD, pathogen-specific quantity cut-offs were
113 applied to assign etiology, based on the strong associations of those quantities with

114 diarrhoea previously observed in MAL-ED and GEMS (3,4). However, there was a
115 residual benefit of azithromycin among episodes with bacteria detected at a lower
116 quantity. For example, children with a likely bacterial aetiology had a 3.1% absolute
117 reduction in risk of 90-day hospitalization or death when treated with azithromycin
118 compared to a 2.3% reduction among children with bacteria detected but not attributed
119 (7). These findings suggest the previously used cut-offs likely missed true bacterial
120 episodes that also responded to treatment.

121
122 The ABCD study provides a unique opportunity to further explore diarrhoeal aetiology
123 based on azithromycin treatment response. Azithromycin is a broad-spectrum antibiotic
124 with known efficacy against Gram-negative pathogens, including ETEC (8)
125 *Campylobacter* spp (9) and *Shigella* spp (10,11). We therefore expect an azithromycin
126 treatment response in many cases of diarrhoea in which bacteria are the true
127 aetiological agent. We investigated if heterogeneity in the treatment response by
128 pathogen quantity can further refine aetiological quantity cut-offs for enteric bacteria
129 leading to more precise aetiologic assignment of diarrhoeal episodes.

130

131 **Methods**

132 The ABCD study design (12), primary analysis results (6), and post-hoc analyses
133 incorporating qPCR enteric pathogen testing (13) have been previously described.
134 Briefly, children 2-23 months of age were enrolled between June 2017 and July 2019
135 from seven sites in Bangladesh, India, Kenya, Malawi, Mali, Pakistan, and Tanzania if
136 they presented to study hospitals with acute watery diarrhoea. To be included, children

137 had to have some or severe dehydration and/or moderate wasting or severe stunting,
138 as previously defined (12) and could not have received antibiotics in the 2 weeks prior
139 to presentation. Children with clear indications for antibiotic treatment (i.e., dysentery,
140 severe acute malnutrition, signs of other infections requiring antibiotics) were excluded.

141

142 Enrolled children were randomized to receive either three days of azithromycin (10
143 mg/kg/day) or placebo. Before randomisation, study staff collected whole stool or a
144 flocced rectal swab which was tested for enteric pathogens by qPCR for the first
145 approximately 1,000 children enrolled at each site, using the TaqMan array card
146 platform as described previously (12). To account for differences in sample type, cycle
147 thresholds (Ct's) derived from rectal swabs were adjusted by the pathogen-specific
148 mean cycle threshold difference between paired rectal swabs and whole stools. Follow-
149 up visits were conducted to ascertain presence of diarrhoea on day 3 after enrolment
150 and rehospitalisation and vital status 90 days after enrolment.

151

152 Pathogens were analysed using the continuous Ct as a marker of relative pathogen
153 quantity. To define co-aetiologies (i.e., coinfections at a quantity associated with
154 diarrhoea), we used the pathogen-specific qPCR Ct cut-offs derived for ABCD (7) from
155 two large multisite studies of diarrhoea that included non-diarrhoeal controls, GEMS (3)
156 and MAL-ED (4). A co-aetiology was defined as the detection of any other pathogen at
157 a quantity above (or equally, a qPCR Ct below) the aetiological cut-off. To maximize
158 power to detect treatment effect heterogeneity and to be consistent with prior analyses

159 (7), the primary outcome assessed in this analysis was presence of diarrhoea 3 days
160 after enrolment. As a secondary outcome, we considered a combined outcome of
161 rehospitalisation or death by 90 days after enrolment.

162

163 For each pathogen previously associated with diarrhoea (3) or with at least 5%
164 prevalence, we modelled the heterogeneity in the azithromycin treatment effect by
165 pathogen quantity detected using log-binomial regression adjusting for the day of
166 diarrhoea on which the sample was collected and co-detection of other pathogens. Co-
167 detection of other pathogens was specified with two variables representing the sum of
168 the episode-specific attributable fractions for all bacteria and the sum of the episode-
169 specific attributable fractions for all viruses and protozoa. Episode-specific attributable
170 fractions (AFes) were derived using attribution models from GEMS and MAL-ED by
171 applying pathogen quantities from ABCD diarrhoea episodes and taking the median of
172 1000 estimates drawn equally from each of the site-specific models (5). We first
173 included an interaction term between treatment arm assignment and the quantity of
174 pathogen detected when specified with a linear and quadratic term. We conducted a
175 linear trend test for each interaction using the Wald-based p-value for the quadratic
176 interaction term with $\alpha = 0.05$. Because the test was not statistically significant for
177 13 of 15 pathogens evaluated (Table S1), we proceeded with modelling the interactions
178 with only linear terms for pathogen quantity across all pathogens for interpretability and
179 comparability. For the diarrhoea on day 3 outcome, we further stratified the models by
180 presence of a bacterial co-aetiology.

181

182 We report the model-predicted pathogen quantity and treatment arm-specific risk of
183 each outcome conditional on sample collection at day 0 and no co-detections using
184 ggpredict from the ggeffects package v. 1.2.1 in R v. 4.2.1. We report the risk ratio for
185 azithromycin compared to placebo for each outcome by pathogen quantity using the
186 interplot 0.2.3 package, both overall and stratified by presence of a bacterial co-
187 aetiology for the diarrhoea on day 3 outcome. These data were summarized by
188 reporting the change in the effect of azithromycin per each log₁₀ increase in pathogen
189 quantity based on the interaction term between pathogen quantity and azithromycin. To
190 estimate the proportion of episodes that could be attributed to each bacterial pathogen
191 based on the azithromycin treatment response, we calculated population attributable
192 fractions from these episode-specific risk ratios for day 3 diarrhea. Specifically, to
193 remove azithromycin effects unrelated to the pathogen detected, we divided each
194 episode-specific risk ratio by the largest risk ratio when pathogen quantity was zero
195 (RR_{adj}). The population attributable fraction was then calculated as $\sum_{i=1}^n 1 - RR_{adj_i}$ (since
196 azithromycin is protective) where i included all episodes in which the pathogen was
197 detected at any quantity. Adjusted risk ratios were constrained to be less than or equal
198 to 1 such that the episode attributable fraction could not be negative.

199

200 Finally, across the range of cycle threshold values, we calculated the proportion of
201 diarrhoea episodes that would be treated with antibiotics if a given pathogen-specific
202 cycle threshold were chosen as the cut-off to define aetiology and assign treatment.
203 This proportion was calculated among diarrhoea episodes overall to quantify the
204 proportion of all diarrhoea episodes that would be treated using a given cut-off and

205 among diarrhoea episodes with the pathogen detected at any quantity to quantify the
206 proportion of all potentially pathogen-attributable episodes that would be treated.

207

208 **Results**

209 We included 6692 children who were among the first 1000 enrolled at each of the seven
210 ABCD trial sites and had their samples tested by qPCR with valid a result. This
211 represents 80.9% of all children enrolled in the ABCD trial (n=8268). The density of
212 quantities detected for each pathogen was similar between azithromycin and placebo
213 groups (Figure S1).

214

215 The overall risk of diarrhoea on day 3 was 10.2% and was higher in the placebo
216 (12.0%) compared to azithromycin (8.4%) group. For a subset of the enteric bacteria,
217 specifically *Shigella*, ST-EPEC, tEPEC, and *Vibrio cholerae*, azithromycin was more
218 strongly protective for diarrhoea on day 3 as pathogen quantity detected increased. For
219 these pathogens, the risk of diarrhoea on day 3 in the placebo group increased with
220 increasing pathogen quantity, while the risk in the azithromycin group was less
221 dependent on pathogen quantity (Figure 1A). Correspondingly, the effect of
222 azithromycin became stronger (i.e., risk ratios further from the null) as pathogen
223 quantities increased (Figure 1B). The heterogeneity in azithromycin effect by pathogen
224 quantity was most striking and statistically significant only for *Shigella*. The risk ratio for
225 diarrhoea on day 3 for azithromycin compared to placebo was 13% (95% CI: 3, 23)
226 lower (i.e., further from the null) per log₁₀ increase in *Shigella* quantity detected (Table

227 1). This translated to detection at a high quantity (Ct = 25) associated with a 50%
228 reduction (95% CI: 30, 64) in diarrhoea on day 3 compared to a 40% reduction (95% CI:
229 33, 75) associated with detection at Ct = 30. A similar pattern was observed for *V.*
230 *cholerae*, ST-EPEC, and tEPEC, though the effect heterogeneity was not statistically
231 significant for these pathogens. When stratifying by whether there was a bacterial co-
232 aetiology, the association between pathogen quantity and azithromycin treatment
233 response was slightly stronger for episodes in which there was no co-aetiology (Figure
234 1C).

235

236 In contrast, there was no association between pathogen quantity detected and
237 azithromycin treatment response for *Campylobacter jejuni/coli*, LT-EPEC, and EAEC.
238 For *C. jejuni/coli*, the risk of diarrhoea on day 3 was higher with increasing pathogen
239 quantities detected in both the azithromycin and placebo groups (Figure 1A). This
240 resulted in risk ratios for diarrhoea on day 3 closer to the null at high *C. jejuni/coli*
241 quantities. For LT-EPEC, the risk of diarrhoea on day 3 was very similar between
242 azithromycin and placebo groups at high quantities detected, and for EAEC, the risk
243 ratio for diarrhoea on day 3 was independent of pathogen quantity.

244

245 For viruses and parasites, the azithromycin treatment response was inversely
246 associated or was not associated with pathogen quantity detected (Figure 2). For
247 example, for rotavirus, norovirus GII, adenovirus 40/41, and astrovirus, the risk ratio of
248 diarrhoea on day 3 was closer to the null with higher pathogen quantities detected.

249 There was no consistent pattern when stratifying by presence of a bacterial co-
250 aetiology. *Cryptosporidium* was an outlier; higher quantities detected were associated
251 with a larger azithromycin treatment response. This was not explained by the presence
252 of a bacterial co-aetiology. Rather, the azithromycin treatment response was more
253 strongly associated with *Cryptosporidium* quantity for episodes without a bacterial co-
254 aetiology.

255

256 These results were consistent for the combined outcome of rehospitalisation or death by
257 day 90, but the associations were less precise and none of the effect heterogeneity was
258 statistically significant (Figure 3 and Figure 4). The risk of death or hospitalisation was
259 4.5% overall, 3.6% in the azithromycin group and 5.3% in the placebo group. For
260 episodes in which *Shigella* was detected at a higher quantity (Ct=25), azithromycin was
261 associated with a 57% reduction (95% CI: 29%, 70%) in rehospitalisation or death,
262 compared to a 44% reduction (95% CI: 37%, 54%) for episodes with *Shigella* detected
263 at a lower Ct=30 quantity. The only discrepant result was for rotavirus, for which higher
264 quantities were associated with slightly stronger azithromycin treatment response.

265

266 Using the azithromycin treatment response as a probe to attribute aetiology, we
267 estimated that 4.14% of episodes could be attributed to *Shigella*, 2.95% could be
268 attributed to ST-EPEC, 2.94% could be attributed to tEPEC, and 0.37% could be
269 attributed to *Vibrio cholerae*. The population attributable fractions for *Campylobacter*
270 *jejuni/coli*, EAEC, and LT-EPEC were zero.

271

272 The proportion of aetiology-specific and overall diarrhoea episodes that would be
273 treated if treatment decisions were based on pathogen quantity cut-offs depended on
274 the distribution of pathogen quantities among aetiology-specific episodes and the
275 distribution of etiologies (Figure 5). For example, treatment of all episodes with tEPEC
276 detected at a Ct of 25 or lower would result in 50% of episodes with tEPEC treated and
277 8% of episodes treated overall. In contrast, treatment of all episodes with *V. cholerae*
278 detected at a Ct of 25 or less would result in only 16.6% of episodes with *V. cholerae*
279 treated and 0.4% of episodes treated overall.

280

281 **Discussion**

282 In this reanalysis of the qPCR data from the ABCD study, the azithromycin treatment
283 response at day 3 was stronger among episodes with higher detected pathogen
284 quantities for some of the most common bacterial causes of diarrhoea: *Shigella*, *V.*
285 *cholerae*, tEPEC, and ST-EPEC. This supports that these bacteria are likely the true
286 aetiology of diarrhoea when detected at high pathogen quantities. While not statistically
287 significant for all pathogens, the observed heterogeneity in effects by pathogen quantity
288 was largely consistent with previous comparisons of qPCR data between diarrhoea
289 cases and non-diarrhoeal controls from GEMS, which showed strong quantity
290 dependent associations between all these bacterial pathogens and diarrhoea, with the
291 exception of tEPEC; the highest quantities of tEPEC were only moderately associated
292 with diarrhoea in GEMS (3). However, tEPEC was strongly associated with mortality in
293 GEMS, providing additional support for tEPEC as an important cause of diarrhoea (15).

294

295 Our data suggest that the relationship between treatment response and bacterial
296 pathogen quantity is approximately linear, making the assignment of a definitive cycle
297 threshold cut-off for diarrhoeal aetiology difficult. Such a cut-off would be needed to
298 define antibiotic treatment decision rules (i.e., treat if quantity < threshold and not if
299 quantity > threshold) as well as to define case definitions for studies with pathogen-
300 specific outcomes (e.g., *Shigella*-attributed diarrhea for a *Shigella* vaccine trial).
301 Pathogen quantity could however be used to guide treatment decisions, for example by
302 choosing to treat at a quantity threshold corresponding to a clinically meaningful
303 treatment benefit if a derivative of this assay becomes available as a point of care test.
304 The choice of threshold should also consider the potential benefits of expanded use of
305 azithromycin to treat episodes of bacterial diarrhoea in the context of the growing
306 azithromycin resistance rates in key Gram-negative bacteria, including *Shigella* spp
307 (16,17).

308

309 The lack of associations between pathogen quantity and azithromycin treatment
310 response for *Campylobacter*, LT-EPEC, and EAEC were consistent with the weaker
311 associations between pathogen quantities and diarrhoea observed for these pathogens
312 in MAL-ED and GEMS (3,4). These prior studies of diarrhoea aetiology attributed
313 relatively few diarrhoea episodes to these pathogens compared to their prevalence
314 during diarrhoea, and our results corroborate that they may be relatively rare causes of
315 diarrhoea in children in low-resource settings who have early and high levels of
316 exposure. Sub-clinical carriage of these pathogens is frequent, complicating the

317 assignment of a cut-off to attribute diarrhoea to this pathogen (18). Low qPCR cut-offs
318 used to attribute *Campylobacter* diarrhoea based on MAL-ED and GEMS, for example
319 used in the previous analysis of the ABCD study, have been criticized as potentially
320 being poorly sensitive (7). However, the lack of treatment response even among
321 episodes with high *Campylobacter* quantity support the use of a low Ct (i.e., high
322 quantity) cut-off for attributing *Campylobacter* aetiology.

323

324 A key purpose of vaccine probe studies is to identify the proportion of disease
325 attributable to the vaccine-targeted pathogen (19). In this “antibiotic probe” study
326 analogue, we estimated population attributable fractions for the bacterial pathogens
327 based on the azithromycin treatment response at observed pathogen quantities. The
328 resulting relative ranking of pathogens matched that previously reported in GEMS and
329 MAL-ED (20,21). However, the proportions attributable were smaller in magnitude, likely
330 because azithromycin is not perfectly effective in preventing diarrhoea on day 3.
331 Importantly, no fraction of diarrhoea could be attributed to *Campylobacter*, EAEC, or LT-
332 ETEC using the azithromycin treatment response as a probe given the inverse
333 associations between quantities of these pathogens and the treatment response.

334

335 We also predominantly observed an inverse association between non-bacterial (virus
336 and parasite) quantities and treatment response at day 3. High viral quantities were
337 strongly associated with poor treatment outcomes, suggesting the true aetiology of
338 these diarrhoeal cases was viral, as we would not expect an azithromycin treatment

339 response in cases of viral diarrhoea. The observation of improved treatment outcomes
340 at lower virus quantities, may be due to the increased likelihood of bacterial co-infection
341 at lower virus quantities, such that the virus was carried at sub-clinical levels while the
342 aetiology was truly bacterial.

343

344 Interestingly, higher quantities of rotavirus were associated with a small reduction in
345 rates of death or hospitalisation at day 90. Dehydration and/or undernourishment were
346 inclusion criteria for the ABCD study. Malnourishment can suppress the immune
347 system; the WHO recommends routine treatment of children with severe acute
348 malnutrition (SAM) with a broad-spectrum antibiotic and in some settings azithromycin
349 administration for SAM has been reported to improve recovery and reduce mortality
350 rates (18). Studies conducted in both Africa and Asia have reported that rotavirus
351 infection is associated with under nutrition (22,23). It is possible that the improved
352 azithromycin treatment outcome observed for higher quantities of rotavirus in this study,
353 is due to the anti-inflammatory effects of azithromycin to treat malnutrition, which may
354 have led to improved recovery from rotavirus infection (24). Further, improved outcomes
355 could also be a result of azithromycin driven gut microbiota ablation, which has
356 previously been shown to enhance humoral immunity and reduce severity of rotavirus
357 diarrhoea (25) .

358

359 For parasites, high *Giardia* quantities were strongly associated with poor treatment
360 outcomes. Interestingly, *Cryptosporidium* was unique amongst the non-bacterial

361 pathogens such that high quantities were associated with improved treatment response
362 at both day 3 and day 90. This improvement was not explained by presence of bacterial
363 co-infections but has been observed previously in a case series of HIV-infected adults
364 (26). The mechanism for improved treatment outcome is unclear, however it is possible
365 that the immunomodulatory effects of azithromycin may again be contributing to
366 improved recovery in *Cryptosporidium* infection.

367

368 This study has some limitations. We had no azithromycin susceptibility data from the
369 bacterial pathogens tested for in this analysis, however phenotypic resistance in
370 commensal *E.coli* from a subset of ABCD participants from all sites was 24% three
371 months after enrolment. It is possible that azithromycin resistance amongst the Gram-
372 negative bacterial pathogens reduced the effect of the azithromycin treatment.
373 Mechanistic studies of azithromycin have shown it exhibits immunomodulatory activity
374 through the regulation of multiple inflammatory pathways (24). Our results may have
375 therefore been confounded by children who did not have bacterial attributable diarrhoea
376 but exhibited a treatment response due to the anti-inflammatory activity of azithromycin.
377 In addition, this study of effect heterogeneity was underpowered since the primary
378 ACBD trial was powered for population-level effects. While few estimates of
379 heterogeneity were statistically significant, changes in the magnitude of the
380 azithromycin effect remain informative. Finally, our dataset is derived from children
381 enrolled in the ABCD study, which had restrictive enrolment criteria requiring all children
382 to have dehydration or malnutrition. Therefore, the estimates of the proportions of
383 children who would be treated under varying quantity cut-offs are not generalizable to all

384 children with diarrhoea. Furthermore, the results may not be generalizable to high-
385 income countries (HICs). *Campylobacter* spp are endemic and show high sub-clinical
386 carriage in LMICs but not in HICs (27). It is feasible that there may be a clearer
387 association between *Campylobacter* quantity and azithromycin treatment response in
388 HIC settings where *Campylobacter* is not endemic.

389

390 In this reanalysis of qPCR diagnostic data from the ABCD trial, the relationship between
391 bacterial quantity and treatment response for *Shigella*, *V. cholerae*, tEPEC, and ST-
392 EAEC support that attribution of diarrhoea aetiology to these pathogens is more
393 accurate as pathogen quantity increases and suggest that the use of a pathogen
394 quantity cut-off to attribute aetiology is appropriate for observational and intervention
395 studies of diarrhoea using molecular diagnostics. However, because the heterogeneity
396 of treatment response was linear with pathogen quantity, the assignment of an
397 aetiological qPCR cut-off remains context specific.

398

399 ***Financial support***

400 The ABCD trial and nested molecular diagnostics study was funded by the Bill &
401 Melinda Gates Foundation (grant numbers OPP 1126331 and OPP 1179069). This
402 study was funded by the Bill & Melinda Gates Foundation (INV-044317 to ETRM).

403

404

405 **References**

- 406 1. Diarrhoeal disease [Internet]. [cited 2024 Apr 24]. Available from:
407 <https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease>
408
- 409 2. WHO. World Health Organization Integrated Management of Childhood Illness (IMCI)
410 Chart Booklet—Standard. Geneva (Switzerland): World Health Organization [Internet].
411 2014 [cited 2024 Aug 26];(March):1–80. Available from:
412 [https://www.who.int/publications/m/item/integrated-management-of-childhood-illness---](https://www.who.int/publications/m/item/integrated-management-of-childhood-illness---chart-booklet-(march-2014))
413 [chart-booklet-\(march-2014\)](https://www.who.int/publications/m/item/integrated-management-of-childhood-illness---chart-booklet-(march-2014))
414
- 415 3. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative
416 molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of
417 the GEMS case-control study. *The Lancet*. 2016 Sep 24;388(10051):1291–301.
418
- 419 4. JA PM, J L, ET R. Use of quantitative molecular diagnostic methods to assess the
420 aetiology, burden, and clinical characteristics of diarrhoea in children in low-resource
421 settings: a reanalysis of the MAL-ED cohort study. *Lancet Glob Health*. 6:e1309-18.
422
- 423 5. Cohen AL, Platts-Mills JA, Nakamura T, Operario DJ, Antoni S, Mwenda JM, et al.
424 Aetiology and incidence of diarrhoea requiring hospitalisation in children under 5 years of
425 age in 28 low-income and middle-income countries: findings from the Global Pediatric
426 Diarrhea Surveillance network. *BMJ Glob Health*. 2022 Sep 1;7(9):e009548.
427
- 428 6. Ahmed T, Chisti MJ, Rahman MW, Alam T, Ahmed D, Parvin I, et al. Effect of 3 Days of
429 Oral Azithromycin on Young Children with Acute Diarrhea in Low-Resource Settings: A
430 Randomized Clinical Trial. *JAMA Netw Open*. 2021 Dec 16;4(12).
431
- 432 7. Pavlinac PB, Platts-Mills JA, Liu J, Atlas HE, Gratz J, Operario D, et al. Azithromycin for
433 Bacterial Watery Diarrhea: A Reanalysis of the AntiBiotics for Children With Severe
434 Diarrhea (ABCD) Trial Incorporating Molecular Diagnostics. *J Infect Dis*. 2024 Apr
435 12;229(4).
436
- 437 8. JW S, RW F, SD P. Azithromycin and loperamide are comparable to levofloxacin and
438 loperamide for the treatment of traveler’s diarrhea in United States military personnel in
439 Turkey. *Clin Infect Dis*. 45:294–301.
440

- 441 9. D V, V T, M SP. Single oral dose of azithromycin versus 5 days of oral erythromycin or no
442 antibiotic in treatment of *Campylobacter* enterocolitis in children: a prospective
443 randomized assessor-blind study. *J Pediatr Gastroenterol Nutr.* 50:404–10.
444
- 445 10. WA K, C S, U D, MA S, ML B. Treatment of shigellosis: V. Comparison of azithromycin
446 and ciprofloxacin. A double-blind, randomized, controlled trial. *Ann Intern Med.* 126:697–
447 703.
448
- 449 11. W B, A A. Randomized comparison of azithromycin versus cefixime for treatment of
450 shigellosis in children. *Pediatr Infect Dis J.* 22:374–7.
451
- 452 12. Team AS. A double-blind placebo-controlled trial of azithromycin to reduce mortality and
453 improve growth in high-risk young children with non-bloody diarrhoea in low resource
454 settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol. *Trials.* 21:71.
455
- 456 13. Pavlinac PB, Platts-Mills JA, Liu J, Atlas HE, Gratz J, Operario D, et al. Azithromycin for
457 Bacterial Watery Diarrhea: A Reanalysis of the AntiBiotics for Children With Severe
458 Diarrhea (ABCD) Trial Incorporating Molecular Diagnostics. *J Infect Dis.* 2024 Apr
459 12;229(4).
460
- 461 14. Platts-Mills JA, McQuade ETR. Assigning Pathogen Etiology for Childhood Diarrhea in
462 High-Burden Settings: A Call for Innovative Approaches. *J Infect Dis.* 2023 Oct
463 1;228(7):814–7.
464
- 465 15. Levine MM, Nasrin D, Acácio S, Bassat Q, Powell H, Tennant SM, et al. Diarrhoeal
466 disease and subsequent risk of death in infants and children residing in low-income and
467 middle-income countries: analysis of the GEMS case-control study and 12-month GEMS-
468 1A follow-on study. *Lancet Glob Health* [Internet]. 2020 Feb 1 [cited 2024 Aug
469 26];8(2):e204. Available from: [/pmc/articles/PMC7025325/](https://pubmed.ncbi.nlm.nih.gov/32025325/)
470
- 471 16. Nuzhat S, Das R, Das S, Islam S Bin, Palit P, Haque MA, et al. Antimicrobial resistance
472 in shigellosis: A surveillance study among urban and rural children over 20 years in
473 Bangladesh. *PLoS One.* 2022 Nov 1;17(11 November).
474
- 475 17. Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, et al. Intercontinental
476 dissemination of azithromycin-resistant shigellosis through sexual transmission: A cross-
477 sectional study. *Lancet Infect Dis.* 2015 Aug 1;15(8):913–21.

478

479 18. Houpt ER, Ferdous T, Ara R, Ibrahim M, Alam MM, Kabir M, et al. Clinical Outcomes of
480 Drug-resistant Shigellosis Treated with Azithromycin in Bangladesh. *Clinical Infectious*
481 *Diseases*. 2021 May 15;72(10):1793–8.

482

483 19. Feikin DR, Scott JAG, Gessner BD. Use of vaccines as probes to define disease burden.
484 *Lancet* [Internet]. 2014 May 5 [cited 2024 Aug 26];383(9930):1762. Available from:
485 [/pmc/articles/PMC4682543/](https://pubmed.ncbi.nlm.nih.gov/24682543/)

486

487 20. Platts-Mills JA, Liu J, Rogawski ET, Kabir F, Lertsethtakarn P, Sigua M, et al. Use of
488 quantitative molecular diagnostic methods to assess the aetiology, burden, and clinical
489 characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-
490 ED cohort study. *Lancet Glob Health* [Internet]. 2018 Dec 1 [cited 2024 Aug
491 26];6(12):e1309. Available from: [/pmc/articles/PMC6227251/](https://pubmed.ncbi.nlm.nih.gov/30227251/)

492

493 21. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative
494 molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of
495 the GEMS case-control study. *Lancet* [Internet]. 2016 Sep 24 [cited 2024 Aug
496 26];388(10051):1291–301. Available from: <https://pubmed.ncbi.nlm.nih.gov/27673470/>

497

498 22. Das SK, Chisti MJ, Sarker MHR, Das J, Ahmed S, Shahunja KM, et al. Long-term impact
499 of changing childhood malnutrition on rotavirus diarrhoea: Two decades of adjusted
500 association with climate and socio-demographic factors from urban Bangladesh. *PLoS*
501 *One* [Internet]. 2017 Sep 1 [cited 2024 Apr 24];12(9). Available from:
502 <https://pubmed.ncbi.nlm.nih.gov/28877163/>

503

504 23. Gasparinho C, Piedade J, Mirante MC, Mendes C, Mayer C, Nery SV, et al.
505 Characterization of rotavirus infection in children with acute gastroenteritis in Bengo
506 province, Northwestern Angola, prior to vaccine introduction. *PLoS One* [Internet]. 2017
507 Apr 1 [cited 2024 Apr 24];12(4). Available from:
508 <https://pubmed.ncbi.nlm.nih.gov/28422995/>

509

510 24. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of
511 macrolides-A systematic review of the underlying mechanisms. *Front Immunol* [Internet].
512 2018 Mar 13 [cited 2024 Apr 24];9(MAR):326197. Available from: www.frontiersin.org

513

- 514 25. Uchiyama R, Chassaing B, Zhang B, Gewirtz AT. Antibiotic Treatment Suppresses
515 Rotavirus Infection and Enhances Specific Humoral Immunity. *J Infect Dis* [Internet]. 2014
516 Jul 7 [cited 2024 Jun 18];210(2):171. Available from: [/pmc/articles/PMC4399425/](#)
517
- 518 26. Kadappu KK, Nagaraja M V., Rao P V., Shastry BA. Azithromycin as treatment for
519 cryptosporidiosis in human immunodeficiency virus disease. *J Postgrad Med* [Internet].
520 2002 Jul [cited 2024 Jun 18];48(3):179–81. Available from:
521 <https://pubmed.ncbi.nlm.nih.gov/12432190/>
522
- 523 27. Epps SVR, Harvey RB, Hume ME, Phillips TD, Anderson RC, Nisbet DJ. Foodborne
524 *Campylobacter*: Infections, Metabolism, Pathogenesis and Reservoirs. *International*
525 *Journal of Environmental Research and Public Health* 2013, Vol 10, Pages 6292-6304
526 [Internet]. 2013 Nov 26 [cited 2024 Apr 24];10(12):6292–304. Available from:
527 <https://www.mdpi.com/1660-4601/10/12/6292/htm>
528
- 529

530 Figure Legends

531 **Figure 1. Modification of the effect of azithromycin on the risk of diarrhoea on day**
532 **3 by bacterial pathogen quantities detected.** For each bacterial pathogen, **A:** the
533 model-predicted risk of diarrhoea on day 3 by pathogen quantity and treatment arm (red
534 = placebo; blue = azithromycin), conditional on sample collection at day 0 and no co-
535 detections. **B:** the risk ratio for azithromycin compared to placebo for diarrhoea on day 3
536 by pathogen quantity adjusted for the day of diarrhoea on which the sample was
537 collected and co-detection of other pathogens. **C:** the adjusted risk ratio for azithromycin
538 compared to placebo for diarrhoea on day 3, stratified by the presence of a bacterial co-
539 aetiology (green = yes; red = no). Pathogen quantity is specified by the cycle threshold
540 value from qPCR (i.e., smaller cycle thresholds correspond to higher pathogen quantity
541 detected). Bands on all plots indicate 95% confidence bands.

542

543 **Figure 2. Modification of the effect of azithromycin on the risk of diarrhoea on day**
544 **3 by non-bacterial pathogen quantities detected.** For each non-bacterial pathogen,
545 **A:** the model-predicted risk of diarrhoea on day 3 by pathogen quantity and treatment
546 arm (red = placebo; blue = azithromycin), conditional on sample collection at day 0 and
547 no co-detections. **B:** the risk ratio for azithromycin compared to placebo for diarrhoea on
548 day 3 by pathogen quantity adjusted for the day of diarrhoea on which the sample was
549 collected and co-detection of other pathogens. **C:** the adjusted risk ratio for azithromycin
550 compared to placebo for diarrhoea on day 3, stratified by the presence of a bacterial co-
551 aetiology (green = yes; red = no). Pathogen quantity is specified by the cycle threshold

552 value from qPCR (i.e., smaller cycle thresholds correspond to higher pathogen quantity
553 detected). Bands on all plots indicate 95% confidence bands.

554

555 **Figure 3. Modification of the effect of azithromycin on rehospitalisation or death**

556 **by day 90 by bacterial pathogen quantities detected.** For each bacterial pathogen,

557 **A:** the model-predicted risk of rehospitalisation or death by pathogen quantity and

558 treatment arm (red = placebo; blue = azithromycin), conditional on sample collection at

559 day 0 and no co-detections. **B:** the risk ratio for azithromycin compared to placebo for

560 rehospitalisation or death by pathogen quantity adjusted for the day of diarrhoea on

561 which the sample was collected and co-detection of other pathogens. Pathogen quantity

562 is specified by the cycle threshold value from qPCR (i.e., smaller cycle thresholds

563 correspond to higher pathogen quantity detected). Bands on all plots indicate 95%

564 confidence bands.

565

566 **Figure 4. Modification of the effect of azithromycin on rehospitalisation or death**

567 **by day 90 by non-bacterial pathogen quantities detected.** For each non-bacterial

568 pathogen, **A:** the model-predicted risk of rehospitalisation or death by pathogen quantity

569 and treatment arm (red = placebo; blue = azithromycin), conditional on sample

570 collection at day 0 and no co-detections. **B:** the risk ratio for azithromycin compared to

571 placebo for rehospitalisation or death by pathogen quantity adjusted for the day of

572 diarrhoea on which the sample was collected and co-detection of other pathogens.

573 Pathogen quantity is specified by the cycle threshold value from qPCR (i.e., smaller

574 cycle thresholds correspond to higher pathogen quantity detected). Bands on all plots
575 indicate 95% confidence bands.


576

577 **Figure 5. Prevalence of antibiotic treatment under decision rules that use cycle**
578 **threshold cut-offs to define aetiology and assign treatment.** The proportion of
579 diarrhoea episodes overall (red line) and diarrhoea episodes with the pathogen detected
580 at any quantity (blue line) that would be treated with antibiotics if a given cycle threshold
581 were chosen as the cut-off to define aetiology and assign treatment.

582 Table 1. Change in the effect of azithromycin on risk of diarrhoea on day 3 and risk
 583 rehospitalisation or death by day 90 for each log₁₀ increase in pathogen quantity
 584 detected among children with watery diarrhoea in the AntiBiotics for Children with
 585 severe Diarrhoea (ABCD) Trial.

Pathogen	Ratio of risk ratios (95% confidence interval)	
	Diarrhoea on Day 3	Rehospitalisation or death by day 90
<i>Shigella</i> /EIEC	0.87 (0.77, 0.97)	0.93 (0.76, 1.13)
<i>V. cholerae</i>	0.89 (0.68, 1.18)	0.96 (0.45, 2.05)
tEPEC	0.93 (0.85, 1.02)	0.98 (0.84, 1.13)
<i>Cryptosporidium</i>	0.94 (0.85, 1.03)	0.87 (0.73, 1.04)
ST-ETEC	0.94 (0.86, 1.02)	1.00 (0.86, 1.15)
<i>Giardia</i>	0.99 (0.87, 1.13)	1.14 (0.95, 1.38)
<i>E. bienuesi</i>	1.00 (0.74, 1.36)	0.70 (0.43, 1.15)
Sapovirus	1.00 (0.88, 1.12)	0.93 (0.74, 1.16)
EAEC	1.01 (0.93, 1.09)	0.87 (0.76, 1.01)
Astrovirus	1.06 (0.92, 1.21)	0.99 (0.76, 1.29)
Norovirus GII	1.06 (0.92, 1.21)	1.04 (0.83, 1.30)
<i>Campylobacter jejuni/coli</i>	1.08 (0.97, 1.19)	1.01 (0.85, 1.21)
Adenovirus 40/41	1.09 (0.98, 1.23)	1.13 (0.96, 1.33)
LT-ETEC	1.10 (0.91, 1.35)	1.17 (0.92, 1.50)
Rotavirus	1.16 (1.06, 1.26)	0.93 (0.78, 1.12)

586




Intervention




Other bacterial co-infection






Intervention





Other bacterial co-infection







Typical EPEC)

Typical EPEC)





ST-ETEC

ST-ETEC





EAEC

EAEC





C. jejuni/C. coli

C. jejuni/C. coli




LT-ETEC

LT-ETEC



Intervention








Intervention

Placebo


Azithromycin




tEPEC




ST-EPEC



EAEC



Campylobacter jejuni/coli



LT-EPEC

